• InnoCare Pharma presented three orelabrutinib studies at the Japanese Society of Hematology meeting, held Oct. 9-11, 2026, in Kyoto.
• A Phase 2 chemotherapy-free combination showed high response rates in elderly, frail patients receiving initial treatment for diffuse large B-cell lymphoma.
• Preliminary Phase 2 results showed deep remissions with a chemotherapy-free combination in newly diagnosed marginal zone lymphoma; recruitment remains ongoing.
• Real-world monotherapy data showed durable survival benefits in chronic lymphocytic leukemia/small lymphocytic lymphoma, with earlier treatment associated with better progression-free survival.
• All three studies reported manageable safety profiles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610160226PRIMZONEFULLFEED9847141) on October 16, 2026, and is solely responsible for the information contained therein.